Asana Medical, Inc., (“Asana” or the “Company”) is an emerging life sciences company focused on the development and commercialization of innovative medical devices for gastrointestinal applications. Asana’s lead product, ExtraCellular Matrix Hydrogel (ECMH), is a hydrogel composed of extracellular matrix derived from porcine tissue. ECMH creates an environment favorable for the body to grow new tissue in place of diseased or damaged tissue. Extracellular matrix has been proven to be safe and effective in esophageal repair, hernia grafts, vaginal slings, and burn and wound dressings. Asana’s novel application of this technology will treat multiple GI diseases, including Ulcerative Colitis, Crohn’s Disease, and Rectal Mucositis. Ulcerative colitis (UC), the disease to which Asana’s breakthrough technology will be applied first, is a debilitating disease that renders the colon dysfunctional.
In May 2015, the Company executed a worldwide exclusive license with the University of Pittsburgh for the core technology to facilitate Asana’s ability to develop and use ECMH, a hydrogel (liquid) form of ECM for GI diseases in the intestinal tract. The License included issued patents related to ExtraCellular Matrix Hydrogel and additional in-process IP related to the core technology’s treatment for Ulcerative Colitis and other gastrointestinal diseases. Asana expects this technology will permit the development of additional devices to treat other GI conditions listed above.
Asana is collaborating with Dr. Stephen Badylak of the McGowan Institute for Regenerative Medicine (University of Pittsburgh), a world-class center for tissue engineering, to develop the Company’s ECMH product and to conduct much of the preclinical work. The Company intends to file with the FDA and to use the US filing to support an application for CE marking, allowing commercialization in the EU.